Antibiotic use attributable to RSV infections during infancy—an international prospective birth cohort study
Open Access
- 9 May 2025
- journal article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 80 (7) , 1803-1812
Abstract
Background: Early-life antibiotic use impacts microbiome composition and contributes to the emergence of antimicrobial resistance. Despite respiratory syncytial virus (RSV) being a leading cause of acute respiratory infections (ARI), accurate estimates of antibiotic use attributable to RSV are lacking. Objectives: To assess RSV-associated antibiotic use during the first year of life. Patients and methods: The RESCEU birth cohort study followed healthy term infants, born (n = 9154) between 1 July 2017 and 31 July 2020 from five European countries, to identify RSV-ARI hospitalizations during infancy. In a nested cohort (n = 993), we performed active RSV surveillance by collecting nasal swabs in case of ARI symptoms during RSV seasons (October–April). Antibiotic use during hospitalization was identified through chart review, while outpatient data were collected via parental questionnaires. Results: In the total cohort, antibiotics were used in 22.8% of RSV hospitalizations (33/145) and 62.5% of RSV intensive care admissions (5/8). In the nested cohort, antibiotics were used in 5.2% of any-severity RSV-ARI (13/250) and 9.9% of medically attended RSV-ARI (13/131). This results in an estimated incidence of 1.3% (95%CI: 0.8–2.0) of healthy term infants receiving ≥1 course of antibiotics associated with RSV infection in their first year, with an incidence rate of 1.1 RSV-associated antibiotic prescriptions per 1000 infant-months (95%CI: 0.6–1.9). As such, RSV accounts for 22.9% of antibiotic prescriptions for ARI during RSV seasons. Conclusions: One in 77 healthy term infants receives antibiotics during RSV infection before their first birthday. Real-world evidence is needed to establish the impact of RSV immunization on antibiotic use during infancy. Clinical Trials Registration: NCT03627572.Keywords
Funding Information
- Innovative Medicines Initiative 2 Joint Undertaking (16019)
- EU’s Horizon 2020 research and innovation programme
- European Federation of Pharmaceutical Industries and Associations
This publication has 39 references indexed in Scilit:
- Burden of RSV infections among young children in primary care: a prospective cohort study in five European countries (2021–23)The Lancet Respiratory Medicine, 2025
- Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal studyThe Lancet Infectious Diseases, 2024
- The full value of immunisation against respiratory syncytial virus for infants younger than 1 year: effects beyond prevention of acute respiratory illnessThe Lancet Infectious Diseases, 2023
- The COVID-19 pandemic as an opportunity for unravelling the causative association between respiratory viruses and pneumococcus-associated disease in young children: a prospective studyEBioMedicine, 2023
- Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trialsThe Lancet Child & Adolescent Health, 2023
- The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort studyThe Lancet Respiratory Medicine, 2022
- Unnecessary antibiotic treatment of children hospitalised with respiratory syncytial virus (RSV) bronchiolitis: risk factors and prescription patternsJournal of Global Antimicrobial Resistance, 2021
- Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meetingVaccine, 2020
- Respiratory syncytial virus infections in children 0–24 months of age in the communityJournal of Infection, 2020
- The role of vaccines in preventing bacterial antimicrobial resistanceNature Medicine, 2018